Mathers C, Boschi-Pinto C, Lopez A, Murray C. Cancer incidence, mortality and survival by site for 14 regions of the world. Lyon, France: World Health Organization; 2001.Google Scholar
Lage H, Duarte N, Coburger C, Hilgeroth A, Ferreira MJU. Antitumor activity of terpenoids against classical and atypical multidrug resistant cancer cells. Phytomed. 2010;17:441–48.CrossrefGoogle Scholar
Carter S, Livingston R. Principle of cancer chemotherapy. In: Carter S, Glatstein E, Livingston R, editors. principles of cancer treatment. New York, NY: McGraw-Hill; 1982. p. 95–110.Google Scholar
Cragg M, Newman D. Natural product drugs discovery in next millennium. Frederick, MD: National Cancer Institute; 2001.Google Scholar
Pandey GS, Chunekar KC, Vidari K, editors. Bhav Prakash Nighantu, vol. 1. Varanasi: Chaukambha Vidya Bhavan, 1998:388–89.Google Scholar
Tripathi YB, Nagwani S, Mishra P, Jha A, Rai SP. Protective effect of Pueraria tuberosa DC. embedded biscuit on cisplatin-induced nephrotoxicity in mice. J Nat Med. 2012;66:109–18.PubMedCrossrefWeb of ScienceGoogle Scholar
Handa SS, Kaul MK. Recent development of some natural products. In: Handa SS, Kaul MK, editors. Supplement to cultivation and utilization of medical plants. Jammu-Tawi: CSIR, RPL; 1996. p. 53–96.Google Scholar
Gupta RS, Sharma R, Sharma A. Antifertility effects of Pueraria tuberosa root extract in male rats. Pharm Biol. 2004;42:3–9.Google Scholar
Tanwar YS, Goyal S, Ramawat KG. Hypolipidemic effects of tubers of Indian Kudzu (Pueraria tuberosa). J Herb Med Toxicol. 2008;2:21–25.Google Scholar
Joshi BS, Kamat VN. Tuberosin, a new pterocarpan from Pueraria tuberosa DC. J Chem Soc Perkin. 1993;9:907–11.Google Scholar
Khan RA, Agarwal PK, Kapil RS. Puetuberosanol an epoxychalcanol from Pueraria tuberosa. Phytochem. 1996;42:42–44.Google Scholar
Bagad AS, Joseph JA, Bhaskaran N, Agarwal A. Comparative evaluation of anti-inflammatory activity of Curcuminoids, Turmerones, and aqueous extract of Curcuma longa. Adv Pharmacol Sc. 2013;Article ID 805756:7 pages.Google Scholar
Van De Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG, Lansenhuijsen MM. A tetrazolium-based colometric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 1994;174:311–20.CrossrefGoogle Scholar
Chiong M, Cartes-Saavedra B, Norambuena-Soto I, Mondaca-Ruff D, Morales PE, Garcia-Miquel M, et al. Mitochondrial metabolism and the control of vascular smooth muscle cell proliferation. Front Cell Dev Biol. 2014;2:72 pages.PubMedGoogle Scholar
Ho-Tin-Noe B, Le Dall J, Gomez D, Louedec L, Vranclex R, El-Bouchtaoui M, et al. Early atheroma-derived agonists of peroxisome proliferator-activated receptor-gamma trigger intramedial angiogenesis in a smooth muscle cell-dependent manner. Circ Res. 2011;109:1003–14.CrossrefWeb of ScienceGoogle Scholar
Ragolia L, Palaia T, Paric E, Maesaka JK. Prostaglandin D2 synthase inhibits the exaggerated growth phenotype of spontaneously hypertensive rat vascular smooth muscle cells. J Biol Chem. 2003;278:22175–81.CrossrefPubMedGoogle Scholar
Freise C, Querfeld U. The lignan (+)-episesamin interferes with TNF-α-induced activation of VSMC via diminished activation of NF-κB, ERK1/2 and AKT and decreased activity of gelatinases. Acta Physiol (Oxf). 2015;213:642–52.PubMedCrossrefGoogle Scholar
Roberts E, Cossigny DAF, Quan GMY. The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer Vol. 2013;Article ID 418340: 8 pages. Hindawi Publications.Google Scholar
About the article
Published Online: 2017-10-18
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: This study was supported with a grant (TETFUND/DESS/NRF/UI IBADAN/STI/VOL. 1/B2.20.11) received from the National Research Foundation of the Tertiary Education Trust Fund (TETFUND), Nigeria.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.